Mercaptopurine (6-MP)

For research use only.

Catalog No.S1305

8 publications

Mercaptopurine (6-MP) Chemical Structure

CAS No. 50-44-2

Mercaptopurine is a widely used antileukemic agent and immunosuppressive drug that inhibits de novo purine synthesis through incorporation of thiopurine methyltransferase metabolites into DNA and RNA.

Selleck's Mercaptopurine (6-MP) has been cited by 8 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Mercaptopurine is a widely used antileukemic agent and immunosuppressive drug that inhibits de novo purine synthesis through incorporation of thiopurine methyltransferase metabolites into DNA and RNA.
Targets
PRPP Amidotransferase [2]
In vitro

Mercaptopurine is widely used to treat malignancies, rheumatic diseases, dermatologic conditions, inflammatory bowel disease, and solid organ transplant rejection. [1] Mercaptopurine inhibits purine nucleotide synthesis and metabolism by inhibiting an enzyme called Phosphoribosyl pyrophosphate amidotransferase (PRPP Amidotransferase). PRPP Amidotransferase is the rate limiting enzyme of purine synthesis. It alters the synthesis and function of RNA and DNA . Mercaptopurine interferes with nucleotide interconversion and glycoprotein synthesis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
L1210 leukemia cells MYTGeY5kfGmxbjDhd5NigQ>? NXPzfGFrUW6qaXLpeI9zgSClb37j[Y51emG2aX;uJI9vKG23bITp[JJ2\y2{ZYPpd5RidnRiTEGyNVAhdGW3a3XtbYEh[2WubIOsJGlEPTB;MD6wNlQh|ryP NESwbowyQTB4MUC3
MT4 cells M{S5b3Bzd2yrZnXyZZRqd25iYYPzZZk> Mn\YRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPVESgZ4VtdHNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNUDPxE1? MnnUNVczPTR4Nkm=
human CCRF-CEM cells NXPabHQ{WHKxbHnm[ZJifGmxbjDhd5NigQ>? MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEOFUl[tR2VOKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0yKM7:TR?= MV[xO|I2PDZ4OR?=
human CCRF-SB cells M{XQUnBzd2yrZnXyZZRqd25iYYPzZZk> NH3ucWJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPDVmYuW0JiY3XscJMh[nliTWTUJIF{e2G7LDDJR|UxRTFizszN NH3DPJQyPzJ3NE[2PS=>
human SK-MEL-28 cells NV3MUlZlWHKxbHnm[ZJifGmxbjDhd5NigQ>? NULmOGJVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT{1OTUxvMkigZ4VtdHNiYomgUXRVKGG|c3H5MEBKSzVyPUG1JO69VQ>? Ml3VNVczPTR4Nkm=
human MCF7 cells MUHQdo9tcW[ncnH0bY9vKGG|c3H5 MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYomgUXRVKGG|c3H5MEBKSzVyPUOg{txO MmmwNVczPTR4Nkm=
human HepG2 cells MXXQdo9tcW[ncnH0bY9vKGG|c3H5 MnmyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKZYDHNkBk\WyuczDifUBOXFRiYYPzZZktKEmFNUC9PEDPxE1? NX7LVWFFOTd{NUS2Olk>
human DU145 cells MkLaVJJwdGmoZYLheIlwdiCjc4PhfS=> MmrnRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCGVUG0OUBk\WyuczDifUBOXFRiYYPzZZktKEmFNUC9NkDPxE1? NILScJYyPzJ3NE[2PS=>
mouse J774.A1 cells NVPVWotsWHKxbHnm[ZJifGmxbjDhd5NigQ>? NVXJW4d5OyCmYYnz NH;1VmZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFq3O|QvSTFiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JG1VXCClb372[ZJ{cW:wIHHzd4F6NCCLQ{WwQVAvODB|IN88US=> M{LSXlE3PjR|MESw
HEK293 cells NGD0enVRem:uaX\ldoF1cW:wIHHzd4F6 M4XC[lMh\GG7cx?= NIXFboNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGhGUzJ7MzDj[YxteyCjZoTldkA{KGSjeYOgZpkhVVSWIHPvcpZmenOrb36gZZN{[XluIFnDOVA:OC5yMEeg{txO M3:ybVE3PjR|MESw
mouse J774 cells MkDEVJJwdGmoZYLheIlwdiCjc4PhfS=> MXG3NkBp NIHKU25CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFq3O|Qh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIHPlcIwh\3Kxd4ToJIFnfGW{IEeyJIhzeyCkeTDNWHQhdWW2aH;kMEBKSzVyPUCuNFA{KM7:TR?= NVGzOmtJOTB5NUe3NFg>
human PBMC NFTBU3JHfW6ldHnvckBie3OjeR?= M4rCNFQh\GG7cx?= MXjJcohq[mm2aX;uJI9nKFRiY3XscEBucXSxZ3XuMYlv\HWlZXSgZoxie3SxZ3Xu[ZNqeyCrbjDoeY1idiCSQl3DJIFnfGW{IESg[IF6eyxiSVO1NF0xNjF2OUWg{txO MoHUNVg1PjdyMEe=
HeLa cells M{S5cWN6fG:2b4jpZ4l1gSCjc4PhfS=> MXe0PEBp NFnWO3dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KGG2IHzh[{BxcGG|ZTDv[kBoem:5dHigZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1{Lkmg{txO NEDLVIYyQTdzMUm4Oy=>
A549 cells NEfSS5dEgXSxdH;4bYNqfHliYYPzZZk> MUW0PEBp MmTGR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{BifCCuYXegdIhie2Vib3[g[5Jwf3SqIHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PDdizszN MX:xPVcyOTl6Nx?=
MCF7 cells MmnxR5l1d3SxeHnjbZR6KGG|c3H5 NY\XXIl6PDhiaB?= MmfHR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BifCCuYXegdIhie2Vib3[g[5Jwf3SqIHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OS52IN88US=> MV6xPVcyOTl6Nx?=
MT4 cells MVjDfZRwfG:6aXPpeJkh[XO|YYm= MX25OkBp MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNWFQh[2WubIOgbY5n\WO2ZXSge4l1cCCKVFzWMVEh[W[2ZYKgPVYhcHK|IHL5JG1VXCCjc4PhfUwhS0N3ME2wMlEh|ryP MV6yNVc1OTF|MB?=
CCRF-CEM cells NVvNTm1SWHKxbHnm[ZJifGmxbjDhd5NigQ>? M1\SU|k3KGh? MmHxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCFQ2LGMWNGVSClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEBESzVyPUGg{txO MViyNVc1OTF|MB?=
WIL2-NS cells MUjQdo9tcW[ncnH0bY9vKGG|c3H5 MmD1PVYhcA>? MYTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFeLTEKtUnMh[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IF3UWEBie3OjeTygR2M2OD1|IN88US=> MYOyNVc1OTF|MB?=
CCRF-SB cells NV7xTo52WHKxbHnm[ZJifGmxbjDhd5NigQ>? NIfXeY86PiCq M4iyWmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQ1PSSk1USiClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEBESzVyPUGuNUDPxE1? NHXmRnIzOTd2MUGzNC=>
human DU145 cells NFTMNWRRem:uaX\ldoF1cW:wIHHzd4F6 NVH6d2JmQTZiaB?= MYrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JINmdGy|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIFPDOVA:OiEQvF2= NH[3U|QzOTd2MUGzNC=>
human HepG2 cells NIDDTHNRem:uaX\ldoF1cW:wIHHzd4F6 MoDXPVYhcA>? MUnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIFPDOVA:QCEQvF2= M1fNTVIyPzRzMUOw
MCF7 cells NYnuWXp6WHKxbHnm[ZJifGmxbjDhd5NigQ>? NGS5[m46PiCq MmnVRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPQ1[3JINmdGy|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIFPDOVA:Oy5{IN88US=> NYPaXIh2OjF5NEGxN|A>
SK-MEL-28 cells M{HtR3Bzd2yrZnXyZZRqd25iYYPzZZk> NHLBS3o6PiCq MWTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONLV3FUE0zQCClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEBESzVyPUG1JO69VQ>? NWCwUlg3OjF5NEGxN|A>
MCF7 cells NEO5eZREgXSxdH;4bYNqfHliYYPzZZk> NVjpbGxbS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyxiSVO1NF0zNjd7IN88US=> M4PFSlI{PDFzOUG1
mouse S49 cells M3TldmN6fG:2b4jpZ4l1gSCjc4PhfS=> M2nxcFczKGh? NVrafINOS3m2b4TvfIlkcXS7IHHnZYlve3Rid3ns[EB1gXCnIH3veZNmKFN2OTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nlidIL5dIFvKGKudXWg[ZhkdHW|aX;uJIF{e2G7LDDFR|UxRThizszN NETNdWkzOjF4NUi=
Colo-357 cells NWjLWppWS3m2b4TvfIlkcXS7IHHzd4F6 NETxRm9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBEd2yxLUO1O{Bk\WyuczDifUBkenm|dHHsJJZqd2yndDDzeIFqdmmwZzygTWM2OD14LkGyJO69VQ>? M1HhXVIxQTNyMUKz
Aspc-1 cells NYfuUXZVS3m2b4TvfIlkcXS7IHHzd4F6 MofrR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRZNx[y1zIHPlcIx{KGK7IHPyfZN1[WxidnnvcIV1KHO2YXnubY5oNCCLQ{WwQVIvPDVizszN NH25VmYzODl|MEGyNy=>
A549 cells MmrUR5l1d3SxeHnjbZR6KGG|c3H5 NWfGRlNkPDhiaB?= NHX6O5lEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OFch|ryP MXSyNlcxPTByMR?=
MCF7 cells NYPFU3ViS3m2b4TvfIlkcXS7IHHzd4F6 M3nkRVQ5KGh? M{TL[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2xMlQh|ryP NEHScFAzOjdyNUCwNS=>
Patu-02 cells M2HNWWN6fG:2b4jpZ4l1gSCjc4PhfS=> NEXZOFREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBR[XS3LUCyJINmdGy|IHL5JINzgXO2YXygeolwdGW2IIP0ZYlvcW6pLDDJR|UxRTlwNkmg{txO MYqyNFk{ODF{Mx?=
Patu-T cells MYTDfZRwfG:6aXPpeJkh[XO|YYm= MXvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQZZR2NVRiY3XscJMh[nliY4L5d5RidCC4aX;s[ZQhe3SjaX7pcoctKEmFNUC9OE4xQSEQvF2= M2jGd|IxQTNyMUKz
Patu-S cells NFOyXJFEgXSxdH;4bYNqfHliYYPzZZk> MnzyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVIF1fS2VIHPlcIx{KGK7IHPyfZN1[WxidnnvcIV1KHO2YXnubY5oNCCLQ{WwQVEyNjB5IN88US=> M3XSXFIxQTNyMUKz
T3M4 cells NWi3OINnS3m2b4TvfIlkcXS7IHHzd4F6 MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDUN201KGOnbHzzJIJ6KGO{eYP0ZYwhfmmxbHX0JJN1[WmwaX7nMEBKSzVyPUKuOlMh|ryP NWjJWWQ{OjB7M{CxNlM>
human PANC1 cells MV\DfZRwfG:6aXPpeJkh[XO|YYm= M4LzO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBCVkNzIHPlcIx{KGK7IHPyfZN1[WxidnnvcIV1KHO2YXnubY5oNCCLQ{WwQVYvOzlizszN MnLkNlA6OzBzMkO=
human DAN-G cells MlfaR5l1d3SxeHnjbZR6KGG|c3H5 NXixRocyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTEGQLVegZ4VtdHNiYomgZ5J6e3SjbDD2bY9t\XRic4ThbY5qdmduIFnDOVA:PC5yNjFOwG0> NGDLbokzODl|MEGyNy=>
HeLa cells NXru[pRZS3m2b4TvfIlkcXS7IHHzd4F6 NWjpNYxHPDhiaB?= NUn1UFdGS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWOYTDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVIvQSEQvF2= NFLDNmczOjdyNUCwNS=>
WEHI164 cells M{nxcHBzd2yrZnXyZZRqd25iYYPzZZk> MlrYN{Bl[Xm| M{i5d2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViV1XITVE3PCClZXzsd{Bi\nSncjCzJIRigXNiYomgUXRVKGOxbo\ldpNqd25iYYPzZZktKEmFNUC9NE4xOTVizszN M3rXZ|E3PjR|MESw
WIL-2NS cells MVLQdo9tcW[ncnH0bY9vKGG|c3H5 MnnNRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCZSVytNm5UKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NF0{KM7:TR?= NWrMc2o5OTd{NUS2Olk>
WEHI164 cells MUHQdo9tcW[ncnH0bY9vKGG|c3H5 MkmwO|IhcA>? MljjRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCZRVjJNVY1KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDj[YxtKGe{b4f0bEBi\nSncjC3NkBpenNiYomgUXRVKG2ndHjv[EwhUUN3ME2wMlAyPyEQvF2= NGf4XWoyODd3N{ewPC=>

... Click to View More Cell Line Experimental Data

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (197.13 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 152.18
Formula

C5H4N4S

CAS No. 50-44-2
Storage powder
in solvent
Synonyms N/A
Smiles C1=NC2=C(N1)C(=S)N=CN2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04770922 Enrolling by invitation -- Acute Lymphoblastic Leukemia Pediatric|Adverse Drug Event Cipherome Inc.|Stanford University February 23 2021 --
NCT03022747 Unknown status Drug: Allopurinol|Drug: Standard treatment Lymphoblastic Leukemia Acute Childhood Vastra Gotaland Region January 2017 Phase 2
NCT04304950 Recruiting Drug: Evening Group|Drug: Morning Group Inflammatory Bowel Diseases Rush University Medical Center April 25 2016 Phase 4
NCT03920813 Enrolling by invitation Drug: Mercaptopurine Acute Lymphoblastic Leukemia Shandong University January 2015 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Mercaptopurine (6-MP) | Mercaptopurine (6-MP) supplier | purchase Mercaptopurine (6-MP) | Mercaptopurine (6-MP) cost | Mercaptopurine (6-MP) manufacturer | order Mercaptopurine (6-MP) | Mercaptopurine (6-MP) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID